I am hereby creating this topic on Panacea bio tech as there’s no dedicated thread on the same.
Panacea Biotec is an Innovation driven Biotechnology company doing Research and Development, Manufacturing, Sales, Distribution and Marketing of Pharmaceuticals and Vaccines.
Panacea Biotec was set up in the year 1984, under the name of Panacea Drugs Private Limited with a commitment to make Innovative Products Affordable and Accessible to the masses. It got publically listed on Indian National Stock Exchanges in September 1995 as Panacea Biotec Ltd.
To summarise the developments:
- They are Globally accredited USFDA approved pharmaceutical manufacturing facility at Baddi
- It’s into phase 3 trials of dengue vaccine
-Panacea Biotec is the first company to have developed World’s first fully-liquid wP-IPV based Hexavalent vaccine (DTwP+HepB+Hib+IPV) EasySix. EasySix was launched in 2017 and millions of doses are produced and supplied in Indian private market.
-it’s biggest development is that it’s “DengiAll” vaccine has entered into Phase 3 trials. It is making this this vaccine with ICMR. If passed, panacea will be the first company to come up with a dengue vaccine in india. Do note, entry of medicine/vaccine into phase 3 trials
Recently,
Panacea Biotec’s Order Book Gets a Boost—UNICEF Ups Contract Value by $8.93M (~₹80 Cr) | MCap 2,184.2 Cr
- UNICEF increases contract value by $2.55M (~₹23 Cr) for 2026, raising total to $16.8M.
- 2027 contract value rises by $2.70M (~₹24 Cr), now totaling $15.18M.
- Additional $3.68M (~₹33 Cr) awarded for Easyfive-TT® supply in 2027.
- Total increase across both years: $8.93M (~₹80 Cr) for Easyfive-TT®.
- No related party transactions involved; UNICEF to publish updated award details.
Any further developments are welcomed. Balance sheet does not look so great but any perspective is welcomed